secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2026-07-28T20:12:49+00:00
Accession:  0001178913-26-003617
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio raises ~$275M in private placement for phase 3 osteoporosis trial; BVF gets board seats
--------------------------------------------------------------------------------

- Raised ~$275M via private placement of 122.96M shares and 11.84M pre-funded warrants at $2.04/share.
- Proceeds to fund phase 3 registrational study of EB613 for postmenopausal osteoporosis and working capital.
- BVF Partners (lead investor) gets right to designate two board directors, subject to ownership thresholds.
- Two current independent directors (Haya Taitel and Yonatan Malca) to resign or not stand for reelection as part of succession plan.
- Company to seek shareholder approval for equity plan increase and executive grants at special meeting in Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326003617/0001178913-26-003617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326003617/zk2635734.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-003617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer